(S)-(+)-Dimethindene maleate: Practical Research Guide

(S)-(+)-Dimethindene maleate is a small-molecule antagonist supplied as the maleate salt under SKU B6734. The product dossier describes selective affinity for the muscarinic acetylcholine receptor subtype M2, with reduced interaction at M1, M3, and M4, and also identifies antagonism at histamine H1 receptors. This profile makes the compound useful for controlled receptor perturbation in autonomic regulation research, cardiovascular physiology studies, and respiratory system function research.

No directly matched paper evidence was supplied for this SKU. Accordingly, the recommendations below are based on the product dossier and general assay-control practice rather than on claimed potency, selectivity ratios, exposure levels, or biological outcomes from an external publication.

What This Product Solves

Many functional assays produce a mixed response when several receptor systems are active. A defined antagonist can help test whether an observed response is consistent with M2 muscarinic receptor involvement. In this context, B6734 provides a practical pharmacological perturbation for experiments examining the muscarinic acetylcholine receptor signaling pathway, especially when the study design includes appropriate receptor and vehicle controls.

The compound does not solve receptor-attribution problems by itself. Its additional H1 antagonism means that responses in preparations with relevant histamine signaling may reflect more than M2 blockade. Reduced interaction with M1, M3, and M4 is also not equivalent to complete absence of activity at those subtypes. The most defensible use is therefore comparative: evaluate the response with and without antagonist, then test whether the result remains consistent across controls or complementary assays.

The material is chemically defined as (S)-N,N-dimethyl-2-(3-(1-(pyridin-2-yl)ethyl)-1H-inden-2-yl)ethanamine maleate, CAS 136152-65-3, with formula C20H24N2·C4H4O4. The product appears as a solid and has a listed molecular weight of 408.5. These details should be recorded in the study worksheet before preparing standards or calculating nominal concentrations.

Protocol Parameters

• Assay: Molar concentration calculation; Value: 408.5 g/mol; Applicability: Preparation of dosing solutions and conversion between mass and molarity; Rationale: Use the listed molecular weight for the maleate salt unless the approved protocol explicitly defines concentrations by another basis; Evidence basis: Product dossier.
• Assay: Aqueous solubility check; Value: ≥20.45 mg/mL in water; Applicability: Initial preparation of aqueous stocks or working solutions; Rationale: Treat this as a product-reported solubility value, then confirm clarity and stability in the actual assay buffer and matrix; Evidence basis: Product dossier.
• Assay: Material identity and lot documentation; Value: CAS 136152-65-3 and 98.00% purity; Applicability: Reagent release, notebook records, and concentration calculations; Rationale: Record the salt identity and lot-specific documentation before use, and distinguish nominal concentration from any protocol-specific purity adjustment; Evidence basis: Product dossier.
• Assay: Solid storage; Value: Desiccated, room-temperature storage; Applicability: Unused solid material between experiments; Rationale: Limit moisture exposure by using a dry storage environment and returning the container promptly after weighing; Evidence basis: Product dossier.
• Assay: Working-solution handling; Value: Use promptly; Applicability: Aqueous solutions prepared for receptor or functional assays; Rationale: Do not plan long-term solution storage when the dossier advises against it; prepare close to the experiment and document preparation time; Evidence basis: Product dossier and workflow recommendation.

Workflow Setup and QC Checklist

Before preparation

1. Confirm the product name, SKU B6734, CAS number, lot, purity, molecular weight, and salt form in the electronic record.
2. Define whether the experiment is intended to interrogate M2-linked signaling, H1-linked signaling, or a mixed physiological response. This decision determines which counterscreens and interpretation limits are required.
3. Choose the assay matrix before making the stock. Water solubility does not guarantee equivalent behavior in protein-containing media, buffered systems, or tissue preparations.

Preparation and dosing

1. Weigh the solid using a calibrated balance and calculate the nominal concentration from the listed molecular weight of the maleate salt. Keep the calculation record with the assay plate or tissue experiment.
2. Prepare the solution using the validated vehicle for the specific assay. Inspect visually for undissolved material, haze, or precipitation after mixing and after addition to the final matrix.
3. Use matched vehicle controls and keep the vehicle exposure consistent across control and antagonist-treated conditions. Add the compound using the same mixing sequence for every condition.
4. Use a pilot concentration series selected from the laboratory’s validated pharmacology range rather than inferring potency from the dossier. Include a no-compound condition and, where relevant, an H1-focused comparator or separate receptor control.

Run acceptance checks

• Confirm that the untreated or vehicle-treated preparation gives the expected baseline before interpreting antagonist effects.
• Record solution appearance, preparation time, dilution steps, and any delay before dosing.
• For receptor-binding or signaling assays, review raw curves and replicate agreement rather than relying only on a fitted summary value.
• For tissue or whole-system experiments, document whether histamine-related physiology could contribute to the measured endpoint.

Related internal guidance

(S)-(+)-Dimethindene maleate: Parameters for M2 Antagonism Studies complements this guide with a parameter-oriented framework for planning M2 antagonism experiments.

(S)-(+)-Dimethindene Maleate: Protocols and QC for M2 Antagonism is relevant when converting the preparation and handling recommendations into a pre-assay QC checklist.

Common Failure Modes and Fixes

Mass-to-molarity error

Problem: The calculation uses a free-base molecular weight or omits the maleate component. Fix: Use 408.5 g/mol for the supplied salt unless the study protocol specifies a different reporting basis, and retain the calculation in the raw-data file.

Apparent solubility is assumed to transfer to the assay

Problem: A clear water preparation becomes cloudy after dilution into buffer, serum-containing medium, or tissue bath solution. Fix: Check the final matrix visually, mix consistently, and reject or document preparations with precipitation. Do not use the dossier’s water-solubility value as a guarantee of matrix compatibility.

M2 effects are confused with H1 effects

Problem: A physiological change is attributed solely to muscarinic M2 blockade in a system where histamine signaling is active. Fix: Add an appropriate H1 comparator or receptor-specific control, and report the dual-antagonist profile when interpreting the result.

Solution storage extends beyond the intended workflow

Problem: A working solution is stored for later experiments despite the product recommendation against long-term solution storage. Fix: Prepare solutions close to use, record preparation time, and avoid carrying an unverified solution into a later run.

Subtype selectivity is overstated

Problem: Reduced interaction with M1, M3, and M4 is reported as absolute subtype exclusivity. Fix: Use cautious language and confirm attribution with assay-specific counterscreens, orthogonal readouts, or genetic controls where available.

Scope and Limitations

B6734 is intended for scientific research use only and is not for diagnostic, therapeutic, or medical applications. The supplied dossier does not establish a universal potency value, binding constant, selectivity ratio, species profile, cell-line response, exposure duration, or long-term solution stability. Those parameters must be determined or justified within the laboratory’s validated system.

The product description supports use as an M2 muscarinic receptor antagonist with additional H1 antagonism, but it does not establish that every observed phenotype is mediated through either receptor. Assay design should therefore include vehicle controls, matrix checks, relevant receptor counterscreens, and transparent reporting of the compound’s dual pharmacology. Results generated in one preparation should not automatically be generalized to another tissue, species, or signaling endpoint.

Conclusion

(S)-(+)-Dimethindene maleate is best used as a controlled pharmacological probe when the experiment can accommodate both M2 muscarinic and H1 histamine receptor antagonism. Reliable workflows should use the maleate molecular weight for calculations, verify solution behavior in the final assay matrix, minimize solution storage, and treat subtype attribution as an experimentally testable conclusion rather than an assumption.